-
Clinical Characteristics Associated with Efficacy and Prognosis among Patients Treated with PD-1/PD-L1 Inhibitors for Early-stage Triple-negative Breast Cancers: A Meta-Analysis Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-28 Yuhan Wei, Yun Wu, Yang Luo, Fei Ma
To assess the efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy for early-stage triple-negative breast cancer (TNBC) patients with different clinical characteristics. Randomized clinical trials for PD-1/PD-L1 inhibitors and chemotherapy combination were included. Pooled analysis of odds ratio (OR) for pathological complete response (pCR) and hazard ratio (HR) for event-free survival (EFS)
-
Involvement of CircRNAs in Regulating The “New Generation of Cancer Hallmarks”: A Special Depiction on Hepatocellular Carcinoma Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-28 Alyaa Dawoud, Rawan Amr Elmasri, Adham H. Mohamed, Abdelhamid Mahmoud, Monica Mosaad Rostom, Rana A. Youness
The concept of ‘Hallmarks of Cancer’ is an approach of reducing the enormous complexity of cancer to a set of guiding principles. As the underlying mechanism of cancer are portrayed, we find that we gain insight and additional aspects of the disease arise. The understanding of the tumor microenvironment (TME) brought a new dimension and led to the discovery of novel hallmarks such as senescent cells
-
Targeted immunotherapy to cancer stem cells: a novel strategy of anticancer immunotherapy Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-28 Shan-Yong Yi, Mei-Zhuo Wei, Ling Zhao
Cancer is a major disease that endangers human health. Cancer drug resistance and relapse are the two main causes contributing to cancer treatment failure. Cancer stem cells (CSCs) are a small fraction of tumor cells that are responsible for tumorigenesis, metastasis, relapse, and resistance to conventional anticancer therapies. Therefore, CSCs are considered to be the root of cancer recurrence, metastasis
-
Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-mutated Myelodysplastic syndrome: A Systematic Review and Meta-Analysis Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-28 Moazzam Shahzad, Qamar Iqbal, Ezza Tariq, Mohammad Ammad-Ud-Din, Atif Butt, Ali Hassan Mushtaq, Fatima Ali, Sibgha Gull Chaudhary, Iqra Anwar, Jesus D. Gonzalez-Lugo, Haitham Abdelhakim, Nausheen Ahmed, Peiman Hematti, Anurag K. Singh, Joseph P. McGuirk, Muhammad Umair Mushtaq
We conducted a systematic review and meta-analysis to evaluate outcomes after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in TP53-mutated myelodysplastic syndromes (MDS). A literature search was performed on PubMed, Cochrane, Embase, and Clinicaltrials.gov. After screening 626 articles, eight studies were included. Data were extracted following the PRISMA guidelines and analyzed
-
-
Incidence of antibody–drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-23 Hengheng Zhang, GuoShuang Shen, Ping Yang, Jinming Li, Zitao Li, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Zhilin Liu, Jiuda Zhao, Yi Zhao
Numerous studies have reported the efficacy of antibody–drug conjugates (ADCs) for treating breast cancer. However, during cytotoxic drug treatment, long-term disabling fatigue is common. Moreover, studies in the relevant literature have indicated that fatigue can significantly increase the incidence of depression and sleep disorders. Therefore, this meta-analysis aims to evaluate the incidence of
-
Patients’ selection and trial matching in early-phase oncology clinical trials Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-23 P. Corbaux, A. Bayle, S. Besle, A. Vinceneux, H. Vanacker, K. Ouali, B. Hanvic, C. Baldini, P.A. Cassier, C. Terret, L. Verlingue
Early-phase clinical trials (EPCT) represent an important part of innovations in medical oncology and a valuable therapeutic option for patients with metastatic cancers, particularly in the era of precision medicine. Nevertheless, adult patients’ participation in oncology clinical trials is low, ranging from 2% to 8% worldwide, with unequal access, and up to 40% risk of early discontinuation in EPCT
-
Filgrastim biosimilar (EP2006): a review of 15 years’ post-approval evidence Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-23 Pere Gascón, Nadia Harbeck, Bernardo L. Rapoport, Ronald Anderson, Ines Brueckmann, Sebastian Howe, Matti Aapro
Filgrastim is approved for several indications, including reduction of the incidence and duration of chemotherapy-induced neutropenia and for stem cell mobilization. The filgrastim biosimilar, EP2006, has been available in Europe since 2009, and in the United States since 2015. In this time, preclinical and clinical data used to support the approval of EP2006 have been published. These data established
-
Cardiovascular complications of ribociclib in breast cancer patients Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-22 Oraianthi Fiste, Evangelos Mavrothalassitis, Kleoniki Apostolidou, Chrysanthi Trika, Michalis Liontos, Konstantinos Koutsoukos, Maria Kaparelou, Constantine Dimitrakakis, Maria Gavriatopoulou, Meletios Athanasios Dimopoulos, Flora Zagouri
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have unprecedentedly advanced hormone-dependent breast cancer treatment paradigm. In the metastatic setting, ribociclib has consistently demonstrated survival benefit in pre-, peri-, and postmenopausal patients, conjugating efficacy with health-related quality of life preservation. Accordingly, the emergence of cardiac and/or vascular adverse events
-
Decoding the puzzle: A multidisciplinary systematic review of adult brainstem glioma Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-22 Tamara Ius, Nicola Montemurro, Giuseppe Lombardi, Jacopo Berardinelli, Andrea Romano, Valeria Barresi, Giulia Cerretti, Alessia Guarnera, Alessandro Tel, Luigi Maria Cavallo, Francesco Pasqualetti, Alberto Feletti
Adult brainstem gliomas (BSGs) are a group of rare central nervous system tumors with varying prognoses and controversial standard treatment strategies. To provide an overview of current trends, a systematic review using the PRISMA guidelines, Class of evidence (CE) and strength of recommendation (SR), was conducted. The review identified 27 studies. Surgery was found to have a positive impact on survival
-
Higher risk of hepatotoxicity associated with cabozantinib in cancer patients Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-15 Zhen Wang, Lili Jiang, Xin Lv, Hang Yin, Zhe Wang, Wenli Li, Yong Liu
The efficacy of cabozantinib has attracted interest in various solid tumors. The primary aim of this study was to evaluate the risk of hepatotoxicity associated with cabozantinib in the patients with cancer. PubMed, Cochrane, and EMBASE databases were searched for published randomized controlled trials (RCTs) from inception to September 9, 2023. The mainly outcomes were all-grade and grade ≥3 elevation
-
Cancer of unknown primary and the «seed and soil» hypothesis. Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-11 Mariya A. Zolotykh, Leysan A. Mingazova, Yuliya V. Filina, Nataliya L. Blatt, Alfiya I. Nesterova, Alexey G. Sabirov, Albert A. Rizvanov, Regina R. Miftakhova
The worldwide incidence rate of cancer of unknown primary (CUP) reaches 5% (). CUP has an alarmingly high mortality rate, with 84% of patients succumbing within the first year following diagnosis (). Under normal circumstances, tumor cell metastasis follows the «» hypothesis, displaying a tissue-specific pattern of cancer cell homing behavior based on the microenvironment composition of secondary organs
-
Should we use nomograms for risk predictions in diffuse large B cell lymphoma patients? A systematic review Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-10 Jelena Jelicic, Thomas Stauffer Larsen, Bosko Andjelic, Karen Juul-Jensen, Zoran Bukumiric
Models based on risk stratification are increasingly reported for Diffuse large B cell lymphoma (DLBCL). Due to a rising interest in nomograms for cancer patients, we aimed to review and critically appraise prognostic models based on nomograms in DLBCL patients. A literature search in PubMed/Embase identified 59 articles that proposed prognostic models for DLBCL by combining parameters of interest
-
Unraveling molecular signatures in rare bone tumors and navigating the cancer pathway landscapes for targeted therapeutics Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-10 Atif Khurshid Wani, Ajit Prakash, Saikat Sena, Nahid Akhtar, Reena Singh, Chirag Chopra, Esti Endah Ariyanti, Deden Mudiana, Nina Dwi Yulia, Farida Rahayu
Rare cancers (RCs), which account for over 20% of cancer cases, face significant research and treatment challenges due to their limited prevalence. This results in suboptimal outcomes compared to more common malignancies. Rare bone tumors (RBTs) constitute 5-10% of rare cancer cases and pose unique diagnostic complexities. The therapeutic potential of anti-cancer drugs for RBTs remains largely unexplored
-
The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-10 Rodrigo Motta-Guerrero, Gonzalo Recondo, Andres Cardona, Luis Corrales, Verónica Arnao, Virgilio E Failoc-Rojas, Carlos Aliaga
Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor mutant (EGFRm) advanced non-small cell lung cancer (NSCLC). Combining TKIs with an angiogenesis inhibitor has shown promise in pre-clinical studies. A systematic search of clinical trials found that combining erlotinib (a first-generation TKI) with bevacizumab or ramucirumab (angiogenesis inhibitors) improved
-
Uncovering the bookshelves of CRISPR-based libraries: Advances and applications in cancer studies Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-10 Nathalia Quintero-Ruiz, Wesley de Lima Oliveira, Marcos Vinicius Esteca, Daniela Campos Granato, Fernando Moreira Simabuco
-
DIETARY RESTRICTION AND HEPATIC CANCER: SYSTEMATIC REVIEW AND META-ANALYSIS OF ANIMAL STUDIES Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-09 Dallyla Jennifer Morais de Sousa, Kynnara Gabriella Feitosa de Oliveira, Irislene Costa Pereira, Glauto Tuquarre Melo do Nascimento, Clenio Oliveira Barrense, Jorddam Almondes Martins, Beatriz de Mello Pereira Rêgo, Tiago Eugênio Oliveira da Silva, Felipe Cavalcanti Carneiro da Silva, Francisco Leonardo Torres-Leal
-
US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-08 Rachel A. Fischer, Isabel Ryan, Kristine De La Torre, Cody Barnett, Viren S. Sehgal, Joan B. Levy, Jason J. Luke, Andrew S. Poklepovic, Marc S. Hurlbert
New treatments have increased survival of patients with melanoma, and methods to monitor patients throughout the disease process are needed. Circulating tumor DNA (ctDNA) is a predictive and prognostic biomarker that may allow routine, real-time monitoring of disease status. We surveyed 44 US physicians to understand their preferences and practice patterns for biomarker and ctDNA testing in their patients
-
Long noncoding RNA expression in acute lymphoblastic leukemia: A systematic review Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-08 Sara Cristina Lobo-Alves, Liana Alves de Oliveira, Gabriela Canalli Kretzschmar, Andressa Eloisa Valengo, Roberto Rosati
Long noncoding RNAs (lncRNAs), as gene expression modulators, are potential players in Acute Lymphoblastic Leukemia (ALL) pathogenesis. We systematically explored current literature on lncRNA expression in ALL to identify lncRNAs consistently reported as differentially expressed (DE) either in ALL versus controls or between ALL subtypes. By comparing articles that provided global expression data for
-
Efficacy of PD-1/PD-L1 immunotherapy on brain metastatic non-small-cell lung cancer and treatment-related adverse events: A systematic review Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-06 William Phillips, Zak Thornton, Lily Andrews, Richard Daly, Julian Higgins, Philippa Davies, Kathreena Kurian
Recent evidence suggests that PD-1/PD-L1 immunotherapy improves outcomes in patients with brain metastatic non-small cell lung cancer. Records were searched electronically on MEDLINE, Embase and BIOSIS. Hazard ratios and their 95% confidence intervals for overall survival and progression free survival, and treatment-related adverse events data were extracted. Risk of bias was assessed in included studies
-
-
A systematic review of patient-derived tumor organoids generation from malignant effusions Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-03 Sofie Seghers, Maxim Le Compte, Jeroen M.H. Hendriks, Paul Van Schil, Annelies Janssens, Reinier Wener, Niels Komen, Hans Prenen, Christophe Deben
This review assesses the possibility of utilizing malignant effusions (MEs) for generating patient-derived tumor organoids (PDTOs). Obtained through minimally invasive procedures MEs broaden the spectrum of organoid sources beyond resection specimens and tissue biopsies. A systematic search yielded 11 articles, detailing the successful generation of 190 ME-PDTOs (122 pleural effusions, 54 malignant
-
Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-03 Xingyu Xiong, Shiyu Zhang, Weitao Zheng, Xinyang Liao, Jie Yang, Hang Xu, Siping Hu, Qiang Wei, Lu Yang
-
Clinical decision support systems for multidisciplinary team decision-making in patients with solid cancer: Composition of an implementation model based on a scoping review Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-03 Mathijs P. Hendriks, Agnes Jager, Kees C.W.J. Ebben, Janine A. van Til, Sabine Siesling
-
Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-02 Fang Cheng, Hongxiang Wang, Weiming Li, Yu Zhang
In the past decade, numerous tyrosine kinase inhibitors (TKIs) have been introduced in the treatment of chronic myeloid leukemia. Given the significant interpatient variability in TKIs pharmacokinetics, potential drug-drug interactions (DDIs) can greatly impact patient therapy. This review aims to discuss the pharmacokinetic characteristics of TKIs, specifically focusing on their absorption, distribution
-
Tumor-associated macrophages in non-small-cell lung cancer: from treatment resistance mechanisms to therapeutic targets Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-02 Zhenjun Huang, Ziqi Xiao, Liqing Yu, Jiayu Liu, Yihan Yang, Wenhao Ouyang
Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related deaths worldwide. Different treatment approaches are typically employed based on the stage of NSCLC. Common clinical treatment methods include surgical resection, drug therapy, and radiation therapy. However, with the introduction and utilization of immune checkpoint inhibitors, cancer treatment has entered a new
-
Updated review on analysis of long non-coding RNAs as emerging diagnostic and therapeutic targets in prostate cancers Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-01 Zongpan Ke, Xuechun Hu, Yixun Liu, Deyun Shen, Muhammad Imran Khan, Jun Xiao
Despite advancements, prostate cancers (PCa) pose a significant global health challenge due to delayed diagnosis and therapeutic resistance. This review delves into the complex landscape of prostate cancer, with a focus on long-noncoding RNAs (lncRNAs). Also explores the influence of aberrant lncRNAs expression in progressive PCa stages, impacting traits like proliferation, invasion, metastasis and
-
UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates? Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-01 Rebecca Ibrahim, Rita Khoury, Tony Ibrahim, Axel Le Cesne, Tarek Assi
-
Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-02-01 Giovanni Luca Ceresoli, Giulio Rossi, Francesco Agustoni, Lucia Bonomi, Paolo Borghetti, Alessandra Bulotta, Clelia Casartelli, Giulio Cerea, Francesca Colonese, Ester del Signore, Giovanna Finocchiaro, Letizia Gianoncelli, Salvatore Grisanti, Martina Maiolani, Fabio Pagni, Claudia Proto, Erika Rijavec, Isabella Vittimberga, Stefano Arcangeli, Andrea Riccardo Filippi
Background Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated. Methods A group of Italian medical and radiation oncologists with expertise in managing patients with ES-SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the consensus on the defined list of statements
-
The treatment of Advanced Melanoma: Current approaches and new challenges Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-29 Andrea Boutros, Elena Croce, Marco Ferrari, Riccardo Gili, Giulia Massaro, Riccardo Marconcini, Luca Arecco, Enrica Teresa Tanda, Francesco Spagnolo
-
Lung Toxicity Induced by Anti-HER2 Antibody- Drug Conjugates for Breast Cancer Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-29 Mengting Chai, Li Li, Huachao Wu, Yue Liu, Zongbi Yi, Haijun Yu
Human epidermal growth factor receptor 2 (HER2) serves as both a prognostic indicator and a therapeutic target for breast cancer. Therefore, anti-HER2 therapy plays a crucial role in the treatment of HER2 positive cancer. Antibody-drug conjugates (ADCs) are composed of a monoclonal antibody, a chemical linker and a payload, wherein their aim is to reduce the toxicity associated with chemotherapy drugs
-
Why does HER2-positive breast cancer metastasize to the brain and what can we do about it? Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-23 Dongyan Xu, Zhengfang Hu, Kaiyue Wang, Shiyao Hu, Yunxiang Zhou, Shizhen Zhang, Yiding Chen, Tao Pan
-
Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-24 Stefano Natangelo, Dario Trapani, Chrysanthi Koukoutzeli, Luca Boscolo Bielo, Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Giuseppe Curigliano
-
RNA-binding proteins in breast cancer: Biological implications and therapeutic opportunities Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-23 Shimeng Wang, Hexing Sun, Guanyuan Chen, Chengyu Wu, Bingmei Sun, Jiajia Lin, Danping Lin, De Zeng, Baohang Lin, Guan Huang, Xiaofeng Lu, Haoyu Lin, Yuanke Liang
-
Feasibility metrics of exercise interventions during chemotherapy: A systematic review Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-23 Neil Kearney, Deirdre Connolly, Sanela Begic, David Mockler, Emer Guinan
-
Primary vascular tumors of bone: A comprehensive literature review on classification, diagnosis and treatment Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-17 Ilaria Tortorelli, Elena Bellan, Benedetta Chiusole, Fabio Murtas, Pietro Ruggieri, Elisa Pala, Mariachiara Cerchiaro, Maria Samaritana Buzzaccarini, Giovanni Scarzello, Marco Krengli, Gianluca Bisinella, Sara Battisti, Antonio Di Maggio, Vittorina Zagonel, Angelo Paolo Dei Tos, Marta Sbaraglia, Antonella Brunello
Primary vascular tumors of bone are a heterogeneous group of neoplasms, ranging from benign hemangiomas to frankly malignant epithelioid hemangioendotheliomas and angiosarcomas. Over the years, their classification has been a matter of discussion, due to morphologic similarities and uncertainty regarding biologic behavior. Over the past decade, with the development of next-generation sequencing, there
-
Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-12 Jiong Liu, Jian Shu
-
Progression of radio-labeled molecular imaging probes targeting chemokine receptors Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-15 Heqing Yi, Lilin Qin, Xuemei Ye, Jinling Song, Jianfeng Ji, Ting Ye, Juan Li, Linfa Li
-
Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-12 Cong Li, Kunhang Li, Shiyu Zhong, Mingzheng Tang, Xin Shi, Yijun Bao
-
The role of liquid biopsy in epithelial ovarian cancer: State of the art Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-11 Luigi Della Corte, Gianluca Russo, Francesco Pepe, Pasquale Pisapia, Michela Dell’Aquila, Umberto Malapelle, Giancarlo Troncone, Giuseppe Bifulco, Pierluigi Giampaolino
The clinical implementation of liquid biopsy has dramatically modified the analytical paradigm for several solid tumors. To date, however, only circulating free DNA (cfDNA) has been approved in clinical practice to select targeted treatments for patients with colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and breast cancer (BC). Interestingly, emerging liquid biopsy analytes in peripheral
-
Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paper Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-10 Matteo Fassan, Valentina Angerilli, Nicola Normanno, Giancarlo Pruneri, Antonio Marchetti, Federica Grillo, Giuseppe Tonini, Aldo Scarpa, Lorenza Rimassa
-
Geriatric predictors of response and adverse events in older patients with cancer treated with immune checkpoint inhibitors: A systematic review Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-09 Asli Özkan, Frederiek van den Bos, Simon P. Mooijaart, Marije Slingerland, Ellen Kapiteijn, Noel F.C.C. de Miranda, Johanneke E.A. Portielje, Nienke A. de Glas
-
New immunotherapy approaches as the most effective treatment for uveal melanoma Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-09 Atefeh Eteghadi, Maryam Ebrahimi, Saeed Heidari keshel
-
Microbiomes in pancreatic cancer can be an accomplice or a weapon Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2024-01-08 Xiaoyu Guo, Pan Wang, Yuan Li, Yawei Chang, Xiaobing Wang
-
-
Non-apoptotic cell death programs in cervical cancer with an emphasis on ferroptosis Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-23 Mohammad Samare-Najaf, Ali Samareh, Amir Savardashtaki, Nastaran Khajehyar, Amir Tajbakhsh, Sina Vakili, Delaram Moghadam, Sanaz Rastegar, Majid Mohsenizadeh, Bahia Namavar Jahromi, Asma Vafadar, Reza Zarei
-
Comprehensive review of solid tumor bone marrow metastasis Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-23 Lanxin Zhang, Fengxi Chen, Lingzhi Xu, Ning Li, Qiping Zhuo, Yijin Guo, Xueqing Wang, Meijie Wen, Zuowei Zhao, Man Li
-
Deciphering the role of KRAS gene in oncogenesis: Focus on signaling pathways, genetic alterations in 3’UTR, KRAS specific miRNAs and therapeutic interventions Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-22 Yogita Chhichholiya, Harsh Vikram Singh, Rajesh Vashistha, Sandeep Singh, Anjana Munshi
-
Biomarkers of fatigue in oncology: A systematic review Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-21 Deveny Vanrusselt, Charlotte Sleurs, Mahnoor Arif, Jurgen Lemiere, Sabine Verschueren, Anne Uyttebroeck
-
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-21 Alessia Belloni, Armanda Pugnaloni, Maria Rita Rippo, Silvia Di Valerio, Chiara Giordani, Antonio Domenico Procopio, Giuseppe Bronte
-
Liquid biopsy in colorectal cancer: onward and upward Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-20 Sara Torresan, Marco de Scordilli, Martina Bortolot, Paola Di Nardo, Luisa Foltran, Arianna Fumagalli, Michela Guardascione, Elena Ongaro, Fabio Puglisi
-
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-20 Giuseppe Lo Russo, Paolo Bironzo, Chiara Bennati, Laura Bonanno, Annamaria Catino, Giulio Metro, Iacopo Petrini, Marco Russano, Antonio Passaro
-
Brain metastases and next-generation anticancer therapies: a survival guide for clinicians Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-20 Angelo Dipasquale, Chiara Barigazzi, Agnese Losurdo, Pasquale Persico, Antonio Di Muzio, Piera Navarria, Federico Pessina, Martin van den Bent, Armando Santoro, Matteo Simonelli
-
Cryotherapy for prevention of chemotherapy induced peripheral neuropathy in breast cancer Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-20 Mihir Tandon, Melissa Yacur, Christiana Brenin, Patrick Dillon
-
Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-19 Wanying Bao, Zhengyu Li
-
Progress in the treatment of malignant ascites Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-19 Yiqiu Wang, Yunting Sun, Xinyue Li, Xiaoli Yu, Keying Zhang, Jinglei Liu, Qingchang Tian, Honghua Zhang, Xiao Du, Shuling Wang
-
Predictors of response to neoadjuvant therapy in urothelial cancer Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-19 Nishita Tripathi, Gliceida Galarza Fortuna, Georges Gebrael, Emre Dal, Vinay Mathew Thomas, Sumati Gupta, Umang Swami
-
Oncogenic Fusions: Targeting NTRK Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-19 Garo Hagopian, Misako Nagasaka
-
Genetic and epigenetic alterations in DNA repair genes and treatment outcome of chemoradiotherapy in cervical cancer Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-19 Atar Singh Kushwah, Shireen Masood, Rajnikant Mishra, Monisha Banerjee
-
Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis Crit. Rev. Oncol. Hematol. (IF 6.2) Pub Date : 2023-12-18 Yicong Wang, Lifeng Liu, Xianyu Jin, Yongai Yu